fig5

Figure 5. Reserpine suppresses release of paclitaxel-induced TEVs in TNBC. (A) Nanoparticle tracking analysis comparing size distribution and concentration of TEV from EO771 cell culture media after 24 h in vehicle, 10 µM reserpine, 100 µM paclitaxel, or both 10 µM reserpine with 100 µM paclitaxel (average of 2 separate collections); (B) Western blot analysis of the EV biomarkers ALIX, flotillin-1 (FLOT-1), CD9, and GAPDH from TEV isolated from EO771 cell culture media after 24 h in vehicle, 10 µM reserpine, 100 µM paclitaxel, or both 10 µM reserpine with 100 µM paclitaxel. TEVs: Tumor-derived extracellular vesicles; TNBC: Triple-negative breast cancer; ALIX: ALG-2-interacting protein X; CD9: Tetraspanin Cluster Domain 9 protein; GAPDH: Glyceraldehyde-3-phosphate dehydrogenase.